FGFR2 and cholangiocarcinoma: Subsequently, the phase II FIGHT-202 trial (NCT02924376) enrolled previously treated CCA patients harboring FGFR2 gene fusions or rearrangements, other FGFR aberrations, or no FGFR aberrations.